The authors noted that treatment with SSRIs led to significantly greater improvement by the second week of treatment vs. SNRIs (P=0.0268); this benefit remained statistically significant through Week 12.
"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.
The dosing droppers, supplied by a third party, were misprinted with the dose markings in reverse number, shifted dose markings or no dose markings.
Study authors reported evidence of greater opioid receipt among commercially insured patients with a wide range of psychiatric conditions.
Tonix announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of posttraumatic stress disorder (PTSD).
Adverse drug events in children due to the ingestion of drugs excreted in breast milk are poorly reported but potentially dangerous.